3 results
Approved WMOCompleted
To study the effect on intraocular pressure in patients using the Travalert dosing aid with or without the additional use of the Eyot and with of without additional patient education.
Approved WMORecruiting
Primary ObjectivePart1: To evaluate the safety and tolerability of intravenous (IV) administration of AL001 over up to 96 weeks in asymptomatic and symptomatic carriersof a granulin (GRN) mutation causative of frontotemporal dementia (FTD) and in…
Approved WMORecruiting
The primary objective of this study is: Part 1: To evaluate the efficacy of AL001 compared with placebo as measured by CDR® plus NACC FTLD-SB.Part 2: To assess the long-term safety and tolerability of AL001 in participants who have completed 96…